147 related articles for article (PubMed ID: 37018875)
1. Direct comparison of [
Ahenkorah S; Cawthorne C; Murce E; Deroose CM; Cardinaels T; Seimbille Y; Bormans G; Ooms M; Cleeren F
Nucl Med Biol; 2023; 118-119():108338. PubMed ID: 37018875
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
[TBL] [Abstract][Full Text] [Related]
3. Automated GMP compliant production of [
Tshibangu T; Cawthorne C; Serdons K; Pauwels E; Gsell W; Bormans G; Deroose CM; Cleeren F
EJNMMI Radiopharm Chem; 2020 Jan; 5(1):4. PubMed ID: 31997090
[TBL] [Abstract][Full Text] [Related]
4.
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
[No Abstract] [Full Text] [Related]
5. Multimodal Imaging of 2-Cycle PRRT with
Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
[TBL] [Abstract][Full Text] [Related]
6. 3p-C-NETA: A versatile and effective chelator for development of Al
Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
[No Abstract] [Full Text] [Related]
7.
Gao F; Zhang Y; Chen M; Song Z; Dong R; Qiu S; Shen C; Huang X; Geng H; Cheng W; Hu J
Eur J Pharm Sci; 2024 Feb; 193():106671. PubMed ID: 38104907
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography.
Dude I; Zhang Z; Rousseau J; Hundal-Jabal N; Colpo N; Merkens H; Lin KS; Bénard F
EJNMMI Radiopharm Chem; 2017; 2(1):4. PubMed ID: 29503845
[TBL] [Abstract][Full Text] [Related]
9. [
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
[TBL] [Abstract][Full Text] [Related]
10. Preparation and Evaluation of [
Dam JH; Langkjær N; Baun C; Olsen BB; Nielsen AY; Thisgaard H
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296411
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
[TBL] [Abstract][Full Text] [Related]
13.
Leupe H; Ahenkorah S; Dekervel J; Unterrainer M; Van Cutsem E; Verslype C; Cleeren F; Deroose CM
J Nucl Med; 2023 Jun; 64(6):835-841. PubMed ID: 37169533
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin Receptor Imaging in Mice with Difference Positive Rate of SSTR2.
Xie Q; Zhou W; Meng X; Ding J; Li D; Lu M; Yang Z; Yu J
Neuroendocrinology; 2023 Nov; ():. PubMed ID: 37926096
[TBL] [Abstract][Full Text] [Related]
15. Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer.
Chen L; Fu H; He H; Lou K; Li Q; Ye J; Feng G; Yu C
Mol Pharm; 2023 Aug; 20(8):4277-4284. PubMed ID: 37463487
[TBL] [Abstract][Full Text] [Related]
16. Second generation Al
Spahn MA; Luyten K; Van Loy T; Sathekge M; Deroose CM; Koole M; Schols D; Vanduffel W; De Vos K; Annaert P; Bormans G; Cleeren F
Nucl Med Biol; 2024; 132-133():108906. PubMed ID: 38518400
[TBL] [Abstract][Full Text] [Related]
17. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
[TBL] [Abstract][Full Text] [Related]
18. Comparison of
Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
[TBL] [Abstract][Full Text] [Related]
19. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
[TBL] [Abstract][Full Text] [Related]
20. Targeting somatostatin receptors: preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET.
Leyton J; Iddon L; Perumal M; Indrevoll B; Glaser M; Robins E; George AJ; Cuthbertson A; Luthra SK; Aboagye EO
J Nucl Med; 2011 Sep; 52(9):1441-8. PubMed ID: 21852355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]